Tata Son’s Chairman Ratan Tata has infused an undisclosed amount in the next generation therapeutic startup Invictus Oncology, the New Delhi based company declared on Monday.

The Tata Investment Tale

Following the Tata Sons patriarch’s investment in startup research platform Tracxn, pet care portal DogSpot, baby and maternity care online retailer FirstCry, as well as in cash-back and coupons venture, CashKaro, all four of which were announced in January and now the investment in Invictus Oncology is Tata’s fifth edition in 2016.

“I have admired Ratan Tata’s insights and astute assessment of technology for decades now, So I am thrilled he has invested in Invictus, which is not just developing ground-breaking innovations for cancer treatment, but is also among the very first startups based out of India to tread the path of novel discovery and biotech innovation,” said Raghunath A. Mashelkar, co-founder of Invictus Oncology.

Invictus Oncology uses supermolecular technology platform to outline anti-cancer drug that home into the tumor, and modify the tumor immune response.The company also claims that that its lead molecule,  IO 125 has already been proved in multiple cancer models and is ensured to enter IND- enabling studies to obtain US Food and Drug Administration (US FDA) consent for initiating clinical studies. “Mr Tata’s investment is a strong affirmation of the quality of the technology that Invictus has developed. We are getting excellent traction from investors, both from India and outside” said Shiladitya Sengupta, co-Founder of Invictus and Assistant Professor of Medicine at Harvard Medical School.